Clinical trial NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Official title: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Treated With Insulin
Lead sponsor: Medtronic Diabetes
Sponsor class: INDUSTRY
First posted: 2022-02-14
Enrollment: 574
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long.

Detailed description: Phase 1 of the study, will utilize the MiniMed™ 780G Insulin pump with Guardian 4 sensor for the run-in period, study period, and optional continued access. Phase 2 of the study will utilize the MiniMed™ 780G BLE2.0 insulin pump with the Disposable Sensor 5 for the run-in period and study period which will be approximately 135 days long. A total of up to 575 subjects with at least 300 subjects entering the study period of Phase 2, with insulin-requiring diabetes age 18-80 will be enrolled at up to 40 investigational centers across the United States.

Eligibility criteria: Inclusion Criteria:

1. Is age 18 - 80 years at time of screening.
2. Has a clinical diagnosis of type 2 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
3. Is on MDI regimen (basal/bolus regimen with long-acting insulin and rapid-acting analogs), defined as greater than or equal to 2 injections per day for at least 3 months prior signing the informed consent, or CSII pump therapy with or without CGM. The investigator will use their discretion to verify that insulin requirements have been stable for the last 3 months prior to screening.
4. Is able to comply with technology, according to Investigator's judgment
5. Does not require a legally authorized representative to consent on their behalf due to mental or intellectual disability.
6. Is willing to perform fingerstick blood glucose measurements as needed.
7. Is willing to wear the system continuously throughout the study.
8. Has a Glycosylated hemoglobin (HbA1c) of less than 10% (as processed by Central Lab) at time of screening visit.

   Note: All HbA1c blood specimens will be sent to and tested by a National Glycohemoglobin Standardization Program (NGSP) certified Central Laboratory. HbA1c testing must follow NGSP standards.
9. Has thyroid-stimulating hormone (TSH) in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
10. Is willing to upload data from the study pump, must have Internet access, and a computer system, or compatible smartphone that meets the requirements for uploading the study pump.
11. Is willing to take one of the following insulins and can financially support the use of insulin preparations as required by the study:

    1. Humalog (insulin lispro injection)
    2. NovoLog/NovoRapid (insulin aspart injection)
    3. Admelog (insulin lispro injection)

Exclusion Criteria:

1. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:

   1. Medical assistance (i.e., Paramedics, Emergency Room \[ER\] or Hospitalization)
   2. Coma
   3. Seizures
2. Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes.
3. Has had diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
4. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
5. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection) at time of screening.
6. Has (Total Daily Dose) of less than 8 units or greater than 250 units at time of screening.
7. Has positive GAD (Glutamic Acid Decarboxylase) Antibody test
8. Is female of child-bearing potential and result of pregnancy test is positive at screening
9. Is sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by the investigator.
10. Is female and plans to become pregnant during the course of the study.
11. Is being treated for hyperthyroidism at time of screening.
12. Has diagnosis of adrenal insufficiency at time of screening.
13. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.

    Note: Intra-articular injections to treat pain (e.g., joint pain, bursitis, etc.) are permitted
14. Is using hydroxyurea at time of screening or plans to use it during the study.
15. Is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks prior to screening.(Note: Did not apply to subjects who transitioned from Phase 1 to Phase 2)
16. Is currently abusing illicit drugs.
17. Is currently abusing marijuana.
18. Is currently abusing prescription drugs.
19. Is currently abusing alcohol.
20. Has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator.
21. Has elective surgery planned that requires general anesthesia during the course of the study.
22. Has sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.
23. Plans to receive red blood cell transfusion or erythropoietin over the course of study participation.
24. Is diagnosed with current eating disorder such as anorexia or bulimia.
25. Has been diagnosed with chronic kidney disease greater than CKD2 that results in chronic anemia.
26. Has a hematocrit that is below the normal reference range of lab used.
27. Is on dialysis.
28. Has serum creatinine of \>2 mg/dL.
29. Has celiac disease that is not adequately treated as determined by the investigator.
30. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
31. Has had any of the following cardiovascular events 1 year or more prior to screening: Myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. Subject may be enrolled if clearance from a board-certified cardiologist is provided prior to or at Screening.
32. Is a member of the research staff involved with the study.
33. Has used a MiniMed 780G pump prior to screening (Note: In Phase 2, this applies to new subjects only).

Primary outcomes:
measure: Primary Safety Endpoint - Change in HbA1c
timeFrame: 3 months
measure: Primary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL)
timeFrame: 3 months
Secondary outcomes:
measure: Secondary Effectiveness Endpoint - Percent of time in range (TIR 70-180 mg/dL)
timeFrame: 3 months
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Medical Investigations
state: Arkansas
city: Escondido
country: United States
facility: Headlands Research California LLC
state: California
city: Loma Linda
country: United States
facility: Loma Linda University Medical Center
state: California
city: Newport Beach
country: United States
facility: Hoag Hospital Newport Beach
state: California
city: San Mateo
country: United States
facility: Mills-Peninsula Medical Center: Diabetes Research Institute
state: California
city: Santa Barbara
country: United States
facility: Sansum Diabetes Research Institute
state: California
city: Jacksonville
country: United States
facility: East Coast Institute for Research
state: Florida
city: Tampa
country: United States
facility: USF Diabetes Center
state: Florida
city: Atlanta
country: United States
facility: Atlanta Diabetes Associates
state: Georgia
city: Canton
country: United States
facility: East Coast Institute for Research
state: Georgia
city: Macon
country: United States
facility: East Coast Institute for Research
state: Georgia
city: Roswell
country: United States
facility: Endocrine Research Solutions
state: Georgia
city: Thomasville
country: United States
facility: Javara
state: Georgia
city: Skokie
country: United States
facility: NorthShore University Health System
state: Illinois
city: West Des Moines
country: United States
facility: Iowa Diabetes Research
state: Iowa
city: Baltimore
country: United States
facility: MedStar Good Samaritan Hospital
state: Maryland
city: Rockville
country: United States
facility: Endocrine & Metabolic Consultants
state: Maryland
city: Saint Louis Park
country: United States
facility: Park Nicollet International Diabetes Center
state: Minnesota
city: Lincoln
country: United States
facility: Bryan Health
state: Nebraska
city: Morristown
country: United States
facility: Atlantic Health System
state: New Jersey
city: Long Island City
country: United States
facility: NYC Research Inc
state: New York
city: New York
country: United States
facility: Northwell Health Physician Partners Endocrinology
state: New York
city: Greenville
country: United States
facility: Physicians East
state: North Carolina
city: Austin
country: United States
facility: Texas Diabetes and Endocrinology
state: Texas
city: Conroe
country: United States
facility: Javara
state: Texas
city: Dallas
country: United States
facility: Velocity Clinical Research
state: Texas
city: Flower Mound
country: United States
facility: Prime Revival Research Institute
state: Texas
city: Houston
country: United States
facility: Houston Methodist Research Institute
state: Texas
city: McKinney
country: United States
facility: Tekton Research
state: Texas
city: Chesapeake
country: United States
facility: Virginia Endocrinology Research
state: Virginia
city: Renton
country: United States
facility: Rainier Clinical Research Center
state: Washington
Study officials:
References: